March Roundup: That’s a Wrap for a Busy Q1
It’s been a busy year so far. And we’re only at the start of April! Find out what we’ve been up to in this blog.
It’s been a busy year so far. And we’re only at the start of April! Find out what we’ve been up to in this blog.
While you may not find yourself Kitesurfing in Barbados, intuitive cell line selection unleashing powerful high throughput capabilities promises to be exhilarating.
For those of us who develop software that supports the biopharmaceutical/life science industry, the challenges and opportunities in digital transformation are painfully obvious and it can be easy to forget that not everyone sees it that way. Let’s try another way…
While 2021 was another challenging year in many respects, the life science industry still managed some notable achievements.
The global community await to hear what the accelerated response to climate change will be from the COP26 Summit starting on Sunday in Glasgow. Here at IDBS we know that identification of true reductions in environmental impact through process modelling and Life Cycle Assessment can only be made with access to quality data. Find out more in our blog.
There was a flurry of activity on social media in June when John Erickson et al. published in Biotechnology and Bioengineering on end-to-end collaboration to transform development and manufacturing of biopharmaceuticals.
One of the lasting legacies of the COVID-19 pandemic is heightened awareness of manufacturing challenges and supply chain vulnerabilities in the biopharma industry and the impact this can have on public health. Issues have occurred at every stage of the supply chain, from the availability of raw materials to quality concerns with active pharmaceutical ingredients (APIs), and finished dosage forms and restrictive cold chain requirements.
In a recent Forbes article, Danaher’s Chief Science officer, Jose-Carlos Gutierrez-Ramos, described the impact of the COVID-19 pandemic as follows:“I believe the biopharma business model has fundamentally changed.
The public consciousness has been flooded with awareness of the previously niche concerns of quality control in drug manufacturing.
The global pandemic is shining a spotlight on the power of biologics, both vaccines and antibody therapeutics, to prevent serious infections and treat disease.
We use cookies and other tracking technologies to ensure that we give you the best experience on our website, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties.
Find out more about the cookies we use here.
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences or managing your cart items. You can set your browser to block or alert you about these cookies, but some parts of the site may not work then.
These cookies allow the provision of enhance functionality and personalization, such as videos, live chats, and form pre-population. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these functionalities may not function properly.
These cookies allow us to count visits and traffic sources, so we can measure and improve the performance of our site. They help us know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is anonymous. If you do not allow these cookies, we will not know when you have visited our site.